| Literature DB >> 30568675 |
Hadis Soroush1, Fatemeh Ghorbani-Bidkorbeh2, Seyed Alireza Mortazavi2, Ali Mehramizi1,3.
Abstract
The aim of this study was to prepare orally disintegrating tablets (ODTs) containing dexamethasone (DEX) by direct compression method with sufficient hardness and rapid disintegration time. In order to save time, money, and human resources in designing and improvement of formulation, the statistical software Design Expert is used. Box-Behnken response surface methodology was applied to evaluate and optimize the effects of concentrations of three excipients, Kollidon CL-SF (X1), Pearlitol SD200 (X2), and Prosolv SMCC (X3) as independent factors on four responses: percentage of drug released after 5 min, disintegrating time, hardness, and friability. Thirteen formulations offered by the Box-Behnken design were prepared by direct compression method and ultimate weight of 200 mg, while the amount of DEX was 4 mg. All formulations were characterized for parameters such as diameter, hardness, weight, thickness, friability, and disintegration time. Following the statistical results, the effects of independent variables on responses were evaluated and the optimum formulation regarding acceptable responses consisted of 15% Kollidon, 39.66% Pearlitol, and 7.5% Prosolv which showed 95.28% release of the drug after 5 min, disintegrating time of 30 sec, 6.1 kg hardness, and 0.12% of friability with an acceptable taste as the optimized formulation.Entities:
Keywords: Design of experiment; Dexamethasone; Optimization; Orally disintegrating tablet
Year: 2018 PMID: 30568675 PMCID: PMC6269575
Source DB: PubMed Journal: Iran J Pharm Res ISSN: 1726-6882 Impact factor: 1.696
The Dependent and Independent Variables Used in Box-Behnken design to optimize the formulation
|
| |||
|---|---|---|---|
|
|
|
| |
| Independent variable, factor | 5 | 10 | 15 |
| X 2: Pearlitol SD200 concentration | 25 | 35 | 45 |
| X 3: Prosolv SMCC concentration | 2.5 | 5 | 7.5 |
| Dependent variable, response | Constraints | ||
| Y 1 = drug released after 5 min (%) | Maximize | ||
| Y 2 = disintegration time (s) | Minimize | ||
| Y 3 = hardness (kg) | Maximize | ||
| Y 4 = friability (kg) | Minimize | ||
Dexamethasone orally disintegrating tablet formulations and their precompression parameters
|
|
| ||||||||
|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
|
|
|
| |
| 1 | 2 | 10 | 25 | 7.5 | 1 | 54.5 | 16.77 | Fair | |
Evaluation of different physical parameters of dexamethasone ODTs
| Batch | Avg. weight ± SD n = 20 |
Thickness (mm)
|
Diameter (mm)
| Surface |
|---|---|---|---|---|
| 1 | 201.26 ± 2.36 | 4.24 ± 0.02 | 8 ± 0.005 | Smooth |
| 2 | 202 ± 1.24 | 4.36 ± 0.01 | 8.05 ± 0.001 | Smooth |
| 3 | 202.6 ± 1.95 | 4.43 ± 0.03 | 8.07 ± 0.001 | Smooth |
| 4 | 202.8 ± 1.39 | 4.20 ± 0.01 | 8 ± 0.010 | Smooth |
| 5 | 200.5 ± 0.53 | 4.25 ± 0.02 | 8.04 ± 0.005 | Smooth |
| 6 | 200.54 ± 0.45 | 4.20 ± 0.98 | 8.02 ± 0.035 | Smooth |
| 7 | 202.42 ± 1.51 | 4.22 ± 0.04 | 8.025 ± 0.015 | Smooth |
| 8 | 201.31 ± 0.78 | 4.30 ± 0.02 | 8.04 ± 0.010 | Smooth |
| 9 | 200.81 ± 0.85 | 4.35 ± 0.01 | 8.07 ± 0.010 | Smooth |
| 10 | 200.67 ± 0.64 | 4.30 ± 0.07 | 8.045 ± 0.007 | Smooth |
| 11 | 201.14 ± 0.82 | 4.37 ± 0.01 | 8.05 ± 0.005 | Smooth |
| 12 | 200.58 ± 0.35 | 4.41 ± 0.01 | 8.06 ± 0.005 | Smooth |
| 13 | 201.5 ± 0.52 | 4.45 ± 0.02 | 8.12 ± 0.014 | Smooth |
Values as Mean ± SD.
Three-factors with measured responses of the Box-Behnken design
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|
| 1 | 10 | 25 | 7.5 | 91.75 | 31 | 5.1 | 0.37 |
| 2 | 15 | 35 | 7.5 | 102.21 | 30 | 4.9 | 0.11 |
| 3 | 15 | 25 | 5 | 87.60 | 32 | 4.8 | 0.33 |
| 4 | 5 | 35 | 7.5 | 91.42 | 34 | 4.6 | 0.33 |
| 5 | 5 | 45 | 5 | 90.50 | 38 | 4.2 | 0.45 |
| 6 | 5 | 35 | 2.5 | 89.70 | 42 | 3.4 | 0.37 |
| 7 | 10 | 45 | 7.5 | 92.90 | 33 | 6.5 | 0.26 |
| 8 | 10 | 45 | 2.5 | 95.05 | 36 | 5.9 | 0.35 |
| 9 | 10 | 35 | 5 | 92.85 | 34 | 5.3 | 0.22 |
| 10 | 5 | 25 | 5 | 80.40 | 35 | 2.8 | 0.48 |
| 11 | 15 | 45 | 5 | 104.62 | 34 | 7 | 0.27 |
| 12 | 10 | 25 | 2.5 | 87.60 | 33 | 3.8 | 0.29 |
| 13 | 15 | 35 | 2.5 | 94.25 | 39 | 4.6 | 0.19 |
Figure 1(a) Response surface and (b) Contour plot of the effect of Kollidon CL- SF(X1) and Pearlitol SD200 (X2) on % Dex released after 5 min (Prosolv Concentration = 7.5%)
Figure 2Dissolution profiles of all formulations in HCl 0.1 N
Figure 3(a) Response surface and (b) Contour plot of the effect of Kollidon CL-SF (X1), Pearlitol SD200 (X2) and Prosolv SMCC (X3) on disintegration time of ODT
Figure 4.(a) Response surface and (b) Contour plot of the effects of Kollidon CL-SF (X1) and Pearlitol SD200 (X2) on ODT hardness
Figure 5(a) Response surface and (b) Contour plot of the effect of Kollidon CL-SF (X1) and Pearlitol SD200 (X2) on ODT friability
The suggested optimum formula with predicted and observed responses, residuals and prediction error%
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|
| X1 (%) | 15 | Y1 (%) | 91.46 | 95.28 | -3.82 | -5.42 |
| X2 | 39.66 | Y2 (sec) | 30.77 | 30.00 | 0.77 | 2.51 |
| X3 | 7.5 | Y3 (kg) | 6.46 | 6.10 | 0.36 | 5.57 |
| Y4 (%) | 0.13 | 0.12 | 0.01 | 7.69 |
Selection of flavours and sweeteners
|
|
| ||||
|---|---|---|---|---|---|
|
|
| ||||
|
|
|
|
|
| |
| Dexamethasone (2%) | 4 | 4 | 4 | 4 | 4 |
| Kollidon CL_SF (15%) | 30 | 30 | 30 | 30 | 30 |
| Pearlitol SD200 (39.66%) | 79.32 | 79.32 | 79.32 | 79.32 | 79.32 |
| Prosolv SMCC (7.5%) | 15 | 15 | 15 | 15 | 15 |
| Pharmatose DCL14 (26.84%) | 53.68 | 53.68 | 53.68 | 53.68 | 53.68 |
| Magnesium stearate (1%) | 2 | 2 | 2 | 2 | 2 |
| Citric acid (3%) | 6 | 6 | 6 | 6 | 6 |
| Sodium chloride (2%) | 4 | 4 | 4 | 4 | 4 |
| Orange flavour (1%) | 2 | ||||
| Lemon flavour (1%) | 2 | 2 | |||
| Peppermint flavour (1%) | 2 | ||||
| Grape flavour (1%) | 2 | ||||
| Saccharin (2%) | 4 | 4 | 4 | 4 | |
| Aspartame (2%) | 4 | ||||
| Total (mg) | 200 | 200 | 200 | 200 | 200 |